# FTC moves to block Edwards Lifesciences' acquisition of JenaValve

The Federal Trade Commission has moved to block Edwards Lifesciences' purchase of JenaValve Technology and its Trilogy transcatheter heart valve system for treating aortic regurgitation. Edwards plans to continue pursuing the deal, with a final determination expected by the end of March 2026.

- Type: Acquisition
- Announced: 2025-08-07
- Where: United States
- Value: $500.0M
- Status: announced
- Products: Trilogy transcatheter heart valve system
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Edwards Lifesciences](https://endata.com/companies/5656.md) (acquirer)
- [JenaValve Technology](https://endata.com/companies/60411.md) (target)
- [JenaValve](https://endata.com/companies/86744.md) (target)

## Sources

- [fiercebiotech.com](https://www.fiercebiotech.com/medtech/ftc-aims-stop-edwards-acquisition-jenavalve), 2025-08-07: "The Federal Trade Commission has moved to block Edwards Lifesciences’ purchase of JenaValve Technology and its transcatheter heart valve implant for treating aortic regurgitation."
- [medicaleconomics.com](https://www.medicaleconomics.com/view/ftc-moves-to-block-edwards-lifesciences-acquisition-of-jenavalve), 2025-08-20: "The FTC filed a complaint arguing that the deal would eliminate competition in the development of transcatheter aortic valve replacement for aortic regurgitation (TAVR-AR)."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.